時間 | 題目 | 講者 |
08:30-09:00 | Welcome Reception |
|
09:00-09:10 | Opening Remark |
|
09:10-09:40 | Trends in Development of Bio-conjugation： Introductions of Various Linker Technologies and Their Applications | 謝義簧 博士 RD Vice President Formosa Laboratories |
09:40-10:10 | Leveraging Platform Knowledge for Successful ADC Process Development | 李威漢 博士 Senior Director OBI Pharma |
10:10-10:40 | Considerations and Challenges for the Development and Manufacturing of ADC | 陳佩君 博士 CEO & President Mycenax |
10:40-11:00 | Coffee Break |
|
11:00-11:40 | Analytical and Biophysical Considerations in the CMC Development of ADCs | Dr. John Hill Managing Director, BDO Affiliate Associate Professor, University of Washington |
11:40-12:10 | Site-specific Glycan Conjugation Platform on Next-generation ADCs : Dual-Payload ADCs and ARCs | 莊士賢 博士 CEO HoneyBear Biosciences |
12:10-13:20 | Lunch |
|
13:20-14:00 | Key Considerations in Preclinical Safety Evaluation of ADCs | 曾湘文 博士 Vice President Level Biotechnology |
14:00-14:30 | A Versatile Drug Bundle Platform and Modular Conjugation Strategies for Developing Efficacious, Stable High-DAR ADCs | 朱鑫懋 博士 CEO T-E Meds |
14:30-15:00 | Obrion Engine™: Driving Multi-Platform Innovations for the Next Generation of ADC Technologies | 王南絢 博士 Associate Director OBI Pharma |
15:00-15:30 | Coffee Break / Networking |
|
15:30-16:10 | ADC Bioanalysis in Focus: Technical, Regulatory, and Practical Perspectives | 蕭世良 博士 Bioanalytical Lab Head Mithra Biotechnology |
16:10-16:50 | Designing Phase 1 Study for Antibody Drug Conjugates | 劉興璟 醫師 Chief Medical Officer Anwita |
16:50-17:00 | Discussion & Networking |
|
本次研討會採線上報名，為有效利用場地空間，每個單位限制2個名額，敬請填寫真實姓名及聯絡方式等必要資訊，於提交報名表單後，我們將於過程中進行審查，並統一以信件形式通知各位審查結果，以確認成功報名。經系統通知「已審核通過」者，方可參與本次活動，恕不接受現場報名，尚祈諒解。
